Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis

Takuji Iwamoto, H. Okamoto, N. Iikuni, M. Takeuchi, Y. Toyama, T. Tomatsu, N. Kamatani, S. Momohara

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objectives. To study the role of monocyte chemoattractant protein-4 (MCP-4)/CCL13 in the pathogenesis of rheumatoid arthritis (RA), we analysed the expression of MCP-4/CCL13 in chondrocytes, synovial fluid and serum from patients with RA and investigated the effect of MCP-4/ CCL13 on the proliferation of synovial cells. Methods. Human articular cartilage specimens were obtained from joints from RA and osteoarthritis (OA) patients and normal joints (controls). Transcript levels of MCP-4 in cartilage were determined by real-time polymerase chain reaction. Protein levels were measured by enzyme-linked immunoassay. Cultured fibroblast-like synoviocytes (FLS) were treated with various concentrations of recombinant MCP-4/CCL13 protein, and cell proliferation was evaluated with a viability assay. Results. The gene expression of MCP-4 was significantly higher in cartilage from RA patients than in that from OA patients (P = 0.00902) and in normal cartilage (P = 0.00902). The concentration of MCP-4/CCL13 protein in serum from RA patients (mean 94.7 ± 37.6pg/ml) was significantly higher than in serum from OA patients (mean 49.2 ± 31.2pg/ml, P = 0.0051) and controls (mean 32.6 ± 23.9pg/ml, P = 0.0001). The concentration of MCP-4/CCL13 protein in synovial fluid from RA patients (mean 247.2 ± 161.2/pg/ml) was also significantly higher than in that from OA patients (mean 29.6 ± 50.5pg/ml, P = 0.000019). Moreover, MCP-4/CCL13 enhanced the proliferation of FLS in a dose-dependent manner. Conclusions. MCP-4/CCL13 is highly expressed in RA joints at the mRNA and protein levels. Our results suggest that MCP-4/CCL13 is secreted from chondrocytes and activates the proliferation of rheumatoid synovial cells, thereby leading to joint destruction in RA.

Original languageEnglish
Pages (from-to)421-424
Number of pages4
JournalRheumatology
Volume45
Issue number4
DOIs
Publication statusPublished - 2006 Apr

Fingerprint

Monocyte Chemoattractant Proteins
Cartilage
Rheumatoid Arthritis
Osteoarthritis
Joints
Synovial Fluid
Chondrocytes
Proteins
Fibroblasts
Cell Proliferation
Articular Cartilage
Serum
Immunoenzyme Techniques
Recombinant Proteins

Keywords

  • Chemokines
  • Monocyte chemoattractant protein-4
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. / Iwamoto, Takuji; Okamoto, H.; Iikuni, N.; Takeuchi, M.; Toyama, Y.; Tomatsu, T.; Kamatani, N.; Momohara, S.

In: Rheumatology, Vol. 45, No. 4, 04.2006, p. 421-424.

Research output: Contribution to journalArticle

Iwamoto, T, Okamoto, H, Iikuni, N, Takeuchi, M, Toyama, Y, Tomatsu, T, Kamatani, N & Momohara, S 2006, 'Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis', Rheumatology, vol. 45, no. 4, pp. 421-424. https://doi.org/10.1093/rheumatology/kei209
Iwamoto, Takuji ; Okamoto, H. ; Iikuni, N. ; Takeuchi, M. ; Toyama, Y. ; Tomatsu, T. ; Kamatani, N. ; Momohara, S. / Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. In: Rheumatology. 2006 ; Vol. 45, No. 4. pp. 421-424.
@article{88942a0e89fe49e88b42c71465bf658c,
title = "Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis",
abstract = "Objectives. To study the role of monocyte chemoattractant protein-4 (MCP-4)/CCL13 in the pathogenesis of rheumatoid arthritis (RA), we analysed the expression of MCP-4/CCL13 in chondrocytes, synovial fluid and serum from patients with RA and investigated the effect of MCP-4/ CCL13 on the proliferation of synovial cells. Methods. Human articular cartilage specimens were obtained from joints from RA and osteoarthritis (OA) patients and normal joints (controls). Transcript levels of MCP-4 in cartilage were determined by real-time polymerase chain reaction. Protein levels were measured by enzyme-linked immunoassay. Cultured fibroblast-like synoviocytes (FLS) were treated with various concentrations of recombinant MCP-4/CCL13 protein, and cell proliferation was evaluated with a viability assay. Results. The gene expression of MCP-4 was significantly higher in cartilage from RA patients than in that from OA patients (P = 0.00902) and in normal cartilage (P = 0.00902). The concentration of MCP-4/CCL13 protein in serum from RA patients (mean 94.7 ± 37.6pg/ml) was significantly higher than in serum from OA patients (mean 49.2 ± 31.2pg/ml, P = 0.0051) and controls (mean 32.6 ± 23.9pg/ml, P = 0.0001). The concentration of MCP-4/CCL13 protein in synovial fluid from RA patients (mean 247.2 ± 161.2/pg/ml) was also significantly higher than in that from OA patients (mean 29.6 ± 50.5pg/ml, P = 0.000019). Moreover, MCP-4/CCL13 enhanced the proliferation of FLS in a dose-dependent manner. Conclusions. MCP-4/CCL13 is highly expressed in RA joints at the mRNA and protein levels. Our results suggest that MCP-4/CCL13 is secreted from chondrocytes and activates the proliferation of rheumatoid synovial cells, thereby leading to joint destruction in RA.",
keywords = "Chemokines, Monocyte chemoattractant protein-4, Rheumatoid arthritis",
author = "Takuji Iwamoto and H. Okamoto and N. Iikuni and M. Takeuchi and Y. Toyama and T. Tomatsu and N. Kamatani and S. Momohara",
year = "2006",
month = "4",
doi = "10.1093/rheumatology/kei209",
language = "English",
volume = "45",
pages = "421--424",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis

AU - Iwamoto, Takuji

AU - Okamoto, H.

AU - Iikuni, N.

AU - Takeuchi, M.

AU - Toyama, Y.

AU - Tomatsu, T.

AU - Kamatani, N.

AU - Momohara, S.

PY - 2006/4

Y1 - 2006/4

N2 - Objectives. To study the role of monocyte chemoattractant protein-4 (MCP-4)/CCL13 in the pathogenesis of rheumatoid arthritis (RA), we analysed the expression of MCP-4/CCL13 in chondrocytes, synovial fluid and serum from patients with RA and investigated the effect of MCP-4/ CCL13 on the proliferation of synovial cells. Methods. Human articular cartilage specimens were obtained from joints from RA and osteoarthritis (OA) patients and normal joints (controls). Transcript levels of MCP-4 in cartilage were determined by real-time polymerase chain reaction. Protein levels were measured by enzyme-linked immunoassay. Cultured fibroblast-like synoviocytes (FLS) were treated with various concentrations of recombinant MCP-4/CCL13 protein, and cell proliferation was evaluated with a viability assay. Results. The gene expression of MCP-4 was significantly higher in cartilage from RA patients than in that from OA patients (P = 0.00902) and in normal cartilage (P = 0.00902). The concentration of MCP-4/CCL13 protein in serum from RA patients (mean 94.7 ± 37.6pg/ml) was significantly higher than in serum from OA patients (mean 49.2 ± 31.2pg/ml, P = 0.0051) and controls (mean 32.6 ± 23.9pg/ml, P = 0.0001). The concentration of MCP-4/CCL13 protein in synovial fluid from RA patients (mean 247.2 ± 161.2/pg/ml) was also significantly higher than in that from OA patients (mean 29.6 ± 50.5pg/ml, P = 0.000019). Moreover, MCP-4/CCL13 enhanced the proliferation of FLS in a dose-dependent manner. Conclusions. MCP-4/CCL13 is highly expressed in RA joints at the mRNA and protein levels. Our results suggest that MCP-4/CCL13 is secreted from chondrocytes and activates the proliferation of rheumatoid synovial cells, thereby leading to joint destruction in RA.

AB - Objectives. To study the role of monocyte chemoattractant protein-4 (MCP-4)/CCL13 in the pathogenesis of rheumatoid arthritis (RA), we analysed the expression of MCP-4/CCL13 in chondrocytes, synovial fluid and serum from patients with RA and investigated the effect of MCP-4/ CCL13 on the proliferation of synovial cells. Methods. Human articular cartilage specimens were obtained from joints from RA and osteoarthritis (OA) patients and normal joints (controls). Transcript levels of MCP-4 in cartilage were determined by real-time polymerase chain reaction. Protein levels were measured by enzyme-linked immunoassay. Cultured fibroblast-like synoviocytes (FLS) were treated with various concentrations of recombinant MCP-4/CCL13 protein, and cell proliferation was evaluated with a viability assay. Results. The gene expression of MCP-4 was significantly higher in cartilage from RA patients than in that from OA patients (P = 0.00902) and in normal cartilage (P = 0.00902). The concentration of MCP-4/CCL13 protein in serum from RA patients (mean 94.7 ± 37.6pg/ml) was significantly higher than in serum from OA patients (mean 49.2 ± 31.2pg/ml, P = 0.0051) and controls (mean 32.6 ± 23.9pg/ml, P = 0.0001). The concentration of MCP-4/CCL13 protein in synovial fluid from RA patients (mean 247.2 ± 161.2/pg/ml) was also significantly higher than in that from OA patients (mean 29.6 ± 50.5pg/ml, P = 0.000019). Moreover, MCP-4/CCL13 enhanced the proliferation of FLS in a dose-dependent manner. Conclusions. MCP-4/CCL13 is highly expressed in RA joints at the mRNA and protein levels. Our results suggest that MCP-4/CCL13 is secreted from chondrocytes and activates the proliferation of rheumatoid synovial cells, thereby leading to joint destruction in RA.

KW - Chemokines

KW - Monocyte chemoattractant protein-4

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=33645325979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645325979&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kei209

DO - 10.1093/rheumatology/kei209

M3 - Article

C2 - 16303818

AN - SCOPUS:33645325979

VL - 45

SP - 421

EP - 424

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 4

ER -